IMACS Outcomes Repository

IMACS/JDM Working Group Meeting San Diego, CA; Nov 13, 2005 Lisa Rider, MD and Frederick Miller, MD, PhD Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, DHHS Bethesda, MD

Nov 2005



Outcomes Repository

- Collection of prospective clinical trials and natural history studies that are utilizing common core set measures, demographic/clinical features and outcomes
- Purpose: To prospectively validate and improve definitions of improvement and clinical trial design consensus proposals, especially for therapeutic trials, develop predictors of treatment responses
 - Allows for pooled analyses with sufficient power
 - Contributing investigators qualified for manuscripts using their data
- Restricted access to an Oracle internet database to enter core set measures, demographic, clinical features, and outcomes
 - Password protection for data entry after study approval
 -Under ACR grant, ability to support some data entry for next 1- 2 years
 - Submit study's database once completed with a codebook, description and frequency distribution of variables

Joy 2005



Outcomes Repository— Ethical/Regulatory Issues

- All sites must have U.S. DHHS OHSPR Federal Wide Assurance Agreement and IRBs must have DHHS approval: http://www.hhs.gov/ohrp/
- Possible ways to contribute to the repository include
 - Pl's protocol is approved locally for IMACS data repository at NIH - local subjects will consent to the use of their data for the IMACS repository.
 - PI enrolls subjects in NIEHS IRB approved natural history protocol as a collaborating center.
 - Fully anonymous data entered after data collection requires request for exemption to NIH Office of Human Subjects Research.
- NIH is exempt from HIPAA regulations, but local HIPAA compliance is necessary
 - Anonymized data no date of birth, clinically sensitive data, collapse of race



mas Outcomes Repository -Composition

Required data:

- Core demographic, clinical features and response to therapy data
- IMACS Core Set Activity Measures: MD and Patient/Parent Global Activity, MMT24 (8 key muscles, 0 – 10 point scale preferred), (C)HAQ, Enzymes, MDAA (MyoAct, MITAX)
- Assessment of Study Outcome Improved, Same, Worse
- Clinical Trial Design Elements

Optional data:

- PRINTO/PRCSG Activity Measures: CMAS, DAS (encouraged!)
- Damage: MD and Patient/Parent Global Damage, Myositis Damage Index
- Patient-Reported Outcomes: SF-36, CHQ-PF50
- Ancillary data specific to your study: Submit as a data file to be archived in the registry



Research Study Proposals for Repository and IMACS Group

- IMACS Outcomes Repository open to IMACS investigators for use
- IMACS members propose collaborative clinical trials, natural history studies, and other clinical investigations.
- IMACS members submit research proposal with IRB approval for study to Research Review Committee.
- Research proposals reviewed by Research Committee composed of all contributors to IMACS Outcomes Repository.


Nov 2005



Enter Basic Study Information to Register Your Study and Investigators

https://dir-apps.niehs.nih.gov/imacs/	index.cfm?action=study.edit&studyid=1	<u> </u>	→ Go
Logout	Study Information		
IMACS Membership	Study Number	001	
Current Members	Name of Trial	IMACS NIH Natural History Study	
View/Edit My Profile		INVACO (VIII) (Validial) Instoly Olddy	
Coordinators	Type of Trial	O Clinical Trial	
Assessment Tools		Natural History Study	
About the Tools	Principal Investigator	Rider, Lisa	
Disease Activity Core Set Measures	Assessor Number The PI will automacially be	001	
Disease Damage Core Set Measures	added to the Assessor List below. You may assign a	1	
Patient Reported Outcomes	differnet Assessor Number if you wish.		
IMACS Registry Forms			100
Definitions of Improvement	Centers		
Meetings	001 Environmental Autoimmu	inity Group (NIH)	
About IMACS Meetings	Add New Center	Choose a Center if you wish to Add one	
Meetings	Center Number		
Myositis Studies	It is recommended that you use the defualt value.	To the state of th	
Therapeutic Studies	If you have used different		
Natural History Studies	values in your study, please enter your values		
Media	here.		
News		Update And Return To This Form	
IMACS Publications			
Related Publications	Assessors 001 Lisa Rider		
Resources	003 Frederick Miller		
Sponsors	093 Michael Harris-Love		
Sites of Interest	182 Minal Jain		
Contact Us	603 Michelle Smith		
Contact IMACS	Add New Assessor	Choose an Assessor if you wish to add one to this study 💌	
Data Entry	Assessor Number		
My Studies	It is recommended that you use the defualt value.		
Developer and Beta	If you have used different		

Add Patients to Register Your Study's Patients and Assign ID Numbers





Links to Add or Edit **Specific Core Set Data**

https://dir-apps.niehs.nih.gov/imacs/index.cfm?action=study.details&studyid=1





International Myositis Assessing

IMACS

My Studies

Study Details

General Information

Home

Logout

IMACS Membership

Current Members

View/Edit My Profile

Coordinators

Assessment Tools

About the Tools

Disease Activity Core Set

Measures:

Disease Damage Core Set

Measures

Patient Reported Outcomes

IMACS Registry Forms

Definitions of Improvement

Meetings

About IMACS Meetings

Meetings

Myositis Studies

Therapeutic Studies

Natural History Studies

Media

News

IMACS Publications

Related Publications

Resources

Sponsors

Study Details

You may perform the following action(s)

Edit Basic Study Information -- If you need to make changes to the study information, add centers, or assessors

Add Patients -- If you need to add a new patient

Add/Edit Core Patient data for this Study -- Enter Update and Certify Data for Core Patient (Form 1)

Add/Edit MD Global Acitivity data for this Study -- Enter Update and Certify Data for MD Global Acitivity (Form 2)

Add/Edit Patient Global Activity data for this Study -- Enter Update and Certify Data for Patient Global Activity (Form 3a)

Add/Edit Parent Global Activity data for this Study -- Enter Update and Certify Data for Parent Global Activity (Form 3b)

Add/Edit MMT data for this Study -- Enter Update and Certify Data for MMT (Form 4)

Add/Edit HAQ data for this Study -- Enter Update and Certify Data for HAQ (Form 5a)

Add/Edit CHAQ data for this Study -- Enter Update and Certify Data for CHAQ (Form 5b)

Add/Edit CMAS data for this Study -- Enter Update and Certify Data for CMAS (Form 05c)

Add/Edit Laboratory Measures (Enzymes) data for this Study -- Enter Update and Certify Data for Laboratory Measures (Enzymes) (Form 6)

Add/Edit Myositis Disease Activity Assessment Tool data for this Study -- Enter Update and Certify Data for Myositis Disease Activity Assessment Tool (Form 7)

Add/Edit Myositis Damage Index data for this Study -- Enter Update and Certify Data for Myositis Damage Index (Form 8)



Listing of Patients and Status of Assessments to Add/Edit Data

r-apps.niehs.nih.gov/in	nacs/index.cfm?action=study.details&studyid=1	~
	Patients/Assessments Completed Forms with an asterisk (*) In	ave not been certified by a study assessor.
	001-002 Assessment 1: 06/05/2002 (First Tria	I Assessment)
	Completed Forms 2 - MD Global Acitivity* 4 - MMT	Incomplete Forms 1 - Core Patient 3a - Patient Global Activity 3b - Parent Global Activity 5a - HAQ 5b - CHAQ 05c - CMAS 6 - Laboratory Measures (Enzymes) 7 - Myositis Disease Activity Assessment Tool 8 - Myositis Damage Index 9 - MD Global Damage 10 - Patient Global Damage 11 - Assessment of Study Outcome 12 - Disease Activity Score
	Add Assessment for 001-002	
	001-003 Assessment 1: 01/29/2003 (First Tria	l Assessment)
	Completed Forms 4 - MMT	Incomplete Forms 1 - Core Patient 2 - MD Global Acitivity 3a - Patient Global Activity 3b - Parent Global Activity 5a - HAO 5b - CHAO 05c - CMAS 6 - Laboratory Measures (Enzymes) 7 - Myositis Disease Activity Assessment Tool 8 - Myositis Damage Index 9 - MD Global Damage



Nov 2005

Physician Global Activity

10 of 16

https://dir-apps.niehs.nih.gov/imacs/index.cfm?action=mdactivityassessment.new&assessmentid=161 International myodia. IMACS Add New Physician Global Activity Assessment Add New Physician Global Activity Assessment Notes Disease Activity is defined as potentially reversible pathology or physiology resulting from the myositis. Clinical findings known or suspected to be due to another disease process should not be considered in this evaluation. The global assessment of disease activity is to be judged from all the information available to you today including the subject's appearance, history, physical examination, diagnostic laboratory testing and your resultant medical therapy. Physician Global Activity Assessment Data Study Number - Patient Number 001-003 Assessment Number 001 (On or near: 01/29/2003) **IMACS Assessor** Please Select an Assessor > Assessment Date (month/date/year) Physician Global Activity Assessment, Visual Analog Scale cm Enter 1 digit after the decimal place (i.e. 5.1) (0 - 10 cm) Please rate your global (overall) disease activity assessment by drawing a vertical mark on a 10-cm line according to the following scale: - left end of line = no evidence of disease activity - midpoint of line = moderate disease activity right end of line = extremely active or severe disease activity. Enter the measured result in the box above. Also rate global disease activity on O = none a 5-point Likert scale 1 = mild activity 2 = moderate activity 3 = severe activity 4 = extremely severe activity Data Entry Lisa Rider 11/03/2005



Manual Muscle Testing MMT 0 – 10

Objects District	9	ov/imacs	1																						~	\rightarrow
Study Data		n.	tion	it Nu	mbe		24																			-117
				e Cer			01-0																			
							ot ce																			
		Assess	men			Ma to						2003														
				Ass	esso)93 -	Ha	arris-	Love	е, М	icha	el 💌													
		Asse (mont		nent		0.000	6/02	2/200	03																	
Side		Body us				* (eft S																		
							Z R	ight	Side																	
Axial Muscles	(0-2	0)																								
		N	ach E	Іеког	ac skoke	Axia	H ₃	10 10 00	200 00	200 00	200 0			2000	0220 0	12-0	72.00								-	p.
		136	zen i	icavi	-	0	0) () () () (0 (\circ	0	0 (0	0									
						0	Trac	ce :	1 3	2 :	3	4	5 6 7	8	9 1		Not sses									
		Ne	ck E	xten:	sors	0	0	. 7	2	2	2	~ /	200	0	0	•	0									
						0	Trac	-		2 :	3	4	5 6 7	8		0	Not									
						Ü	ITA					7 8	, ,	•	3 1		sses									
		Axial M	uscle	s (0-	20)								1	67	20											
D	-1	40.400															311									
Proximal Mus	cles	(0-160)				Rig	ht												Le	ft					
Trapezius	_	_	_	_	_	_	- Ing	_	_	^	^	_	_	~	_	-	_	_	_	~	_	-	-	-	^	
	0	0	0	0	0	0	0	0	0	0	0		0	0		0	0	0	0	0	0	0	0	0	•	С
	0	Trace	1	2	3	4	5	6	7	8	9	10	Not Assessed	0	Trace	1	2	3	4	5	6	7	8	9	10	No Asses
					-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	•	0	C
Deltoid middle**	0	0	0	0	0	0																				
Deltoid middle**		O Trace	1	2	3	4	5	6	7	8	9	10	Not Assessed	0	Trace	1	2	3	4	5	6	7	8	9	10	
		10000	0	2	3	4	5	6	7	-	100000	1.00	Not Assessed	0	Trace	1	2	3	4	5	6	7	8	9		No Asses



Laboratory – Enzymes, Cr

Serum Levels Data		
Study Number - Patient Number	001-002	
Assessment Number	001 (On or near: 06/05/2002)	
Assessor	Please Select an Assessor 💌	
Assessment Date (month/date/year)		
Creatine Kinase (CK) (IU/L)	Result	
Adolase (IU/L) Enter 1 digit after the decimal (i.e. 7.6)	Upper Limit of Normal Result Upper Limit of Normal	
Aspartate amino Transferase (AST) or Serum Glutamic Oxalacetic Transaminase (SGOT) (IU/L)		
Alanine Amino Transferase (ALT) or Serum Glutamic Pyruvic Transaminase (SGPT) (IU/L)	Result Upper Limit of Normal	
Lactate dehydrogenase (LDH)		



Options to Edit or Certify Data Once Entered

https://dir-apps.niehs.nih.gov/imacs/index.cfm?action=mdactivityassessment.details&mdactivityassessmentid=2







General Information	
Home	ľ
Logout	l
IMACS Membership	l
Current Members	ı
View/Edit My Profile	ı
Coordinators	ı
Assessment Tools	ı
About the Tools	l
Disease Activity Core Set Measures	
Disease Damage Core Set Measures	
Patient Reported Outcomes	ı
IMACS Registry Forms	ı
Definitions of Improvement	ı
Meetings	ı
About IMACS Meetings	
Meetings	l
Myositis Studies	ı
Therapeutic Studies	ı
Natural History Studies	
Media	ı
News	ı
IMACS Publications	
Related Publications	
Resources	
Sponsors	
Sites of Interest	
Contact Us	
Contact IMACS	I

You may perform the following action(s)

Edit This Score -- Edit the data in a Physician Global Activity Assessment record

Certify This Score -- Certify the data is complete and should not be further edited.

Add/Edit/Certify/View Other Physician Global Activity Assessment Scores -- View (and possibly edit) data for other subjects in this study.

Go to Study 001 -- Edit/View summary data of study. Enter data for study.

Notes

Disease Activity is defined as potentially reversible pathology or physiology resulting from the myositis. Clinical findings known or suspected to be due to another disease process should not be considered in this evaluation. The global assessment of disease activity is to be judged from all the information available to you today including the subject's appearance, history, physical examination, diagnostic laboratory testing and your resultant medical therapy.

Physician Global Activity Assessment Data

Study Number - Patient 001-002 Number

Assessment Number 001 (On or near: 06/05/2002)

IMACS Assessor 001 -- Lisa Rider

Assessment Date 10/24/2005 (month/date/year)

Physician Global Activity 9.1 Assessment, Visual Analog Scale (0 - 10 cm)

Also rate global disease 3 = severe activity activity on a 5-point Likert

Data Entry Lisa Rider


scale

10/31/2005

Data Entry



Certifying Data Locks and Finalizes It





Summary

- IMACS Outcomes Repository is being developed with support of the ACR to validate definitions of improvement, clinical trial design issues and develop predictors of treatment responses
 - All IMACS members are encouraged to submit data from their own trials and studies to the repository
 - Regulatory requirements- local IRB approval or exemption (retrospective), register with DHHS
 - IMACS core set measures and other information needed from a number of clinical studies
- Repository and IMACS Group open for research proposals, following review by the research committee

Nov 2005



Acknowledgements – Sponsors



National Institute of Environmental Health Sciences



National Institute of Arthritis and Musculoskeletal and Skin Diseases



The NIH Office of Rare Diseases



The Myositis Association



American College of Rheumatology